Stockscreener 앱 받기
0.9055
2.11%
-0.0195
시간 외 거래:
.91
0.0045
+0.50%
AEON Biopharma Inc. 주식(AEON)의 최신 뉴스
AEON Technical Analysis | Trend, Signals & Chart Patterns | AEON BIOPHARMA INC (NYSEARCA:AEON) - ChartMill
AEON Biopharma (AEON) details 2026 meeting, director elections and KPMG ratification - Stock Titan
AEON Stock Price, Quote & Chart | AEON BIOPHARMA INC (NYSEARCA:AEON) - ChartMill
AEON Biopharma Sets Annual Shareholder Meeting - The Manila Times
AEON cites going concern audit note, cash into Q3 2026 - Stock Titan
AEON Biopharma receives additional NYSE American non-compliance notice - MSN
AEON Bio (AEON) Stock: Why Brand Strength (Eye on Rally) 2026-04-20Market Movers - Cổng thông tin điện tử tỉnh Tây Ninh
Migraine Market: Pharma Pipeline Fuels Rapid Expansion by 2034 – DelveInsight | Eli Lilly and Company, Axsome Therapeutics, AEON Biopharma, Charleston Laboratories, Amgen, Teva Pharma, Anne Lindblad - Barchart.com
AEON (AEON Biopharma) PB Ratio : (As of Apr. 10, 2026) - GuruFocus
Form 10-QQuarterly report [Sections 13 or 15(d)] - ADVFN
Weekly Earnings: Will AEON Biopharma Inc be affected by tariffs2026 Big Picture & High Conviction Investment Ideas - baoquankhu1.vn
What is the bull case for AEON Bio (AEON) Stock | AEON Q4 2025 Earnings: AEON Biopharma Inc. misses EPS, no revenue postedExpert Stock Picks - Newser
Is AEON Bio (AEON) Stock Rebounding | Price at $0.90, Up 1.27%Crowd Consensus Signals - Cổng thông tin điện tử tỉnh Tây Ninh
AEON Biopharma Receives NYSE American Non-Compliance Notice Due to Stockholders’ Equity Deficit and Ongoing Listing Challenges - Minichart
AEON Biopharma Receives Additional NYSE American Noncompliance Notice - The Globe and Mail
AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711 - The Manila Times
AEON Biopharma, Inc. (AEON) stock price, news, quote and history - Yahoo Finance Singapore
AEON Biopharma Receives Second NYSE American Notice for Listing Non-Compliance - geneonline.com
AEON (AEON) CFO awarded 754,717 restricted stock units vesting over four years - Stock Titan
AEON Biopharma (AEON) CFO John Bencich files initial insider ownership report - Stock Titan
AEON Biopharma Faces Listing Compliance Risk - Intellectia AI
AEON Biopharma Receives Additional Notice Related to NYSE American Continued Listing Standards - The Manila Times
AEON Biopharma Received Notice of Noncompliance - TradingView — Track All Markets
New AEON finance chief gets stock awards tied to NYSE compliance - Stock Titan
Form 8-KCurrent report - ADVFN
AEON stays on NYSE despite $55 million deficit as deadline nears - Stock Titan
AEON Q4 2025 Earnings: AEON Biopharma Inc. Posts Big EPS Miss, No Revenue - Newser
AEON Forecast, Price Target & Analyst Ratings | AEON BIOPHARMA INC (NYSEARCA:AEON) - ChartMill
AEON Biopharma 2025 Financial Review - AlphaStreet
Stock Market Recap: Whats the profit margin of AEON Biopharma Inc - baoquankhu1.vn
AEON Biopharma reports biosimilar progress, secures financing By Investing.com - Investing.com Australia
AEON Biopharma Reports Full Year 2025 Financial Results and Highlights Positive Comparative Analytical Results and FDA Feedback for ABP-450 Biosimilar Program - The Manila Times
Can AEON Biopharma Inc keep up with sector leaders2026 Price Swings & AI Powered Market Entry Strategies - baoquankhu1.vn
AEON Biopharma 2025 10-K: Net loss $39.2M, EPS $(3.95) - TradingView — Track All Markets
AEON Biopharma (AEON) advances Botox biosimilar plan but warns on going concern - Stock Titan
AEON Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
[8-K] AEON Biopharma, Inc. Reports Material Event - Stock Titan
AEON Biopharma reports biosimilar progress, secures financing - Investing.com
AEON's Botox biosimilar matched 3,400 amino acids as FDA mapped next steps - Stock Titan
Latest AEON NewsAEON Biopharma Presents Positive Results fr... - Stock Titan
AEON Biopharma, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Biotech Landscape Update: Regulatory Approvals and Mergers - Intellectia AI
Aeon Biopharma announces FDA feedback after Type 2a meeting - Yahoo Finance
AEON Biopharma receives FDA feedback on botulinum toxin biosimilar - Investing.com
AEON Biopharma Announces FDA Feedback Following BPD Type 2a Meeting for the ABP-450 Biosimilar Program - The Manila Times
FDA maps next steps for AEON's bid to bring a Botox biosimilar - Stock Titan
AEON Biopharma (AEON) Projected to Post Quarterly Earnings on Wednesday - Defense World
If You Invested $1,000 in Aeon Biopharma (AEON) - Stock Titan
AEON Biopharma, Inc.: Fundamental Analysis and Financial Ratings | AEON | US00775E1029 - marketscreener.com
Technical Analysis: Whats the profit margin of AEON Biopharma Inc2026 WrapUp & Weekly Market Pulse Updates - baoquankhu1.vn
Travel Stocks: How much upside does AEON Biopharma Inc haveQuarterly Trade Summary & Expert Curated Trade Setup Alerts - baoquankhu1.vn
Profit Recap: Can AEON Biopharma Inc stock outperform in a bear marketMarket Performance Report & Low Risk Entry Point Guides - baoquankhu1.vn
Risk Analysis: Is AEON Biopharma Inc stock good for income investors2026 Trade Ideas & Safe Entry Point Identification - baoquankhu1.vn
1.77%
0.25%
자본화:
|
볼륨(24시간):